BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate adjuvanted with aluminium hydroxide gel. The vaccine has been developed by Osaka Universty and tested in phase I trials in Japan and Uganda.